Cargando…

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates

Despite considerable investment into potential therapeutic approaches for Alzheimer's disease (AD), currently approved treatment options are limited. Predictive modeling using quantitative systems pharmacology (QSP) can be used to guide the design of clinical trials in AD. This study developed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramakrishnan, Vidya, Friedrich, Christina, Witt, Colleen, Sheehan, Robert, Pryor, Meghan, Atwal, Jasvinder K., Wildsmith, Kristin, Kudrycki, Katherine, Lee, Seung‐Hye, Mazer, Norman, Hofmann, Carsten, Fuji, Reina N., Jin, Jin Y., Ramanujan, Saroja, Dolton, Michael, Quartino, Angelica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835125/ https://www.ncbi.nlm.nih.gov/pubmed/36281062 http://dx.doi.org/10.1002/psp4.12876

Ejemplares similares

Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB
por: Jamalian, Samira, et al.
Publicado: (2023)

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
por: Salloway, Stephen, et al.
Publicado: (2018)

Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach
por: Gadkar, Kapil, et al.
Publicado: (2016)

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial
por: Teng, Edmond, et al.
Publicado: (2022)

gQSPSim: A SimBiology‐Based GUI for Standardized QSP Model Development and Application
por: Hosseini, Iraj, et al.
Publicado: (2020)

Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level
por: Moss, Ronald B., et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
por: Yoshida, Kenta, et al.
Publicado: (2020)

Translational Approaches for Brain Delivery of Biologics via Cerebrospinal Fluid
por: Sadekar, Shraddha S., et al.
Publicado: (2022)

A Flexible Approach for Context‐Dependent Assessment of Quantitative Systems Pharmacology Models
por: Ramanujan, Saroja, et al.
Publicado: (2019)

Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma
por: Kotani, Naoki, et al.
Publicado: (2022)

Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ
por: Meilandt, William J., et al.
Publicado: (2019)

Evidence for impaired amyloid β clearance in Alzheimer's disease
por: Wildsmith, Kristin R, et al.
Publicado: (2013)

Population repeated time‐to‐event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires
por: Svensson, Robin J, et al.
Publicado: (2021)

Quantitative systems pharmacology model‐based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3‐kinase inhibitors
por: Gadkar, Kapil, et al.
Publicado: (2021)

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet
por: Monteiro, Cecilia, et al.
Publicado: (2023)

Prospective Design of Anti‐Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain
por: Kanodia, JS, et al.
Publicado: (2016)

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks
por: Guthrie, Heather, et al.
Publicado: (2020)

In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model
por: Aldea, Roxana, et al.
Publicado: (2022)

Population pharmacokinetics of bevacizumab in cancer patients with external validation
por: Han, Kelong, et al.
Publicado: (2016)

gPKPDSim: a SimBiology(®)-based GUI application for PKPD modeling in drug development
por: Hosseini, Iraj, et al.
Publicado: (2018)

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease
por: Cummings, Jeffrey L., et al.
Publicado: (2018)

Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL
por: Susilo, Monica E., et al.
Publicado: (2023)

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin(®)), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors
por: Quartino, Angelica L., et al.
Publicado: (2018)

Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays
por: Schauer, Stephen P., et al.
Publicado: (2018)

A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies
por: Ferl, Gregory Z., et al.
Publicado: (2018)

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling
por: Hosseini, Iraj, et al.
Publicado: (2020)

Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling
por: Basak, Jacob M, et al.
Publicado: (2012)

Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys
por: Lu, Dan, et al.
Publicado: (2014)

Arquitectura del paisaje : 100 arquitectos 1000 ideas
por: Santos Quartino, Daniela
Publicado: (2016)

A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory
por: Schindler, Emilie, et al.
Publicado: (2018)

Navigating Between Right, Wrong, and Relevant: The Use of Mathematical Modeling in Preclinical Decision Making
por: Kondic, Anna, et al.
Publicado: (2022)

Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patients treated with docetaxel
por: Krishnan, Sreenath M., et al.
Publicado: (2021)

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer
por: Quartino, Angelica L., et al.
Publicado: (2015)

Unraveling the Early Events of Amyloid-β Protein (Aβ) Aggregation: Techniques for the Determination of Aβ Aggregate Size
por: Pryor, N. Elizabeth, et al.
Publicado: (2012)

A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis
por: Kawakatsu, Sonoko, et al.
Publicado: (2021)

Decoding Mammalian Ribosome-mRNA States by Translational GTPase Complexes
por: Shao, Sichen, et al.
Publicado: (2016)

ZNF598 Is a Quality Control Sensor of Collided Ribosomes
por: Juszkiewicz, Szymon, et al.
Publicado: (2018)

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer
por: Quartino, Angelica L., et al.
Publicado: (2017)

SDAR: a practical tool for graphical analysis of two-dimensional data
por: Weeratunga, Saroja, et al.
Publicado: (2012)

Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model
por: Kirouac, Daniel C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dlivcrps8uhmc2cfi5lnio4ibp